Filter Results:
(229)
Show Results For
- All HBS Web
(229)
- News (36)
- Research (167)
- Events (7)
- Multimedia (3)
- Faculty Publications (91)
Show Results For
- All HBS Web
(229)
- News (36)
- Research (167)
- Events (7)
- Multimedia (3)
- Faculty Publications (91)
Page 1 of 229
Results →
- January 2021 (Revised May 2023)
- Case
Pearson: Efficacy 2.0
By: Elie Ofek, Marco Bertini, Oded Koenigsberg and James Weber
Pearson, which billed itself as the "world's learning company," faced a host of critical decisions in mid-2020. Several years prior, it had embarked on a new path that put the learner at the heart of the business and committed to a new strategic orientation. The new... View Details
Keywords: Efficacy; Learning; Outcome or Result; Measurement and Metrics; Brands and Branding; Marketing Communications; Strategic Planning; Education Industry
Ofek, Elie, Marco Bertini, Oded Koenigsberg, and James Weber. "Pearson: Efficacy 2.0." Harvard Business School Case 521-012, January 2021. (Revised May 2023.)
- June 2021
- Teaching Note
Pearson: Efficacy 2.0
By: Elie Ofek and Marco Bertini
Teaching Note for HBS Case No. 521-012. View Details
- 30 Jan 2012
- Research & Ideas
Measuring the Efficacy of the World’s Managers
Firms in the United States, Japan, and Germany tend to be managed especially well, while firms in Brazil, China, and India tend to be managed poorly. Those are among the initial findings of the World Management Survey (WMS), a huge international research initiative to... View Details
Keywords: by Carmen Nobel
- Article
The Efficacy of a Comprehensive Health Project: An Empirical Analysis
By: Robert S. Kaplan, Lester Lave and Samuel Leinhardt
Kaplan, Robert S., Lester Lave, and Samuel Leinhardt. "The Efficacy of a Comprehensive Health Project: An Empirical Analysis." American Journal of Public Health 62, no. 7 (July 1972): 924–930.
- 2012
- Other Unpublished Work
The Efficacy of Shareholder Voting: Evidence from Equity Compensation Plans
By: Ian D. Gow, Christopher S. Armstrong and David F. Larcker
This study examines the effects of shareholder support for equity compensation plans on subsequent chief executive officer (CEO) compensation. Using cross-sectional regression, instrumental variable, and regression discontinuity research designs, we find little... View Details
- Article
The Efficacy of Shareholder Voting: Evidence from Equity Compensation Plans
By: Christopher S. Armstrong, Ian D. Gow and David F. Larcker
Armstrong, Christopher S., Ian D. Gow, and David F. Larcker. "The Efficacy of Shareholder Voting: Evidence from Equity Compensation Plans." Journal of Accounting Research 51, no. 5 (December 2013): 909–950.
- 2016
- Working Paper
Paying for the Truth: The Efficacy of a Peer Prediction Mechanism in the Field
By: Natalia Rigol and Benjamin N. Roth
Rigol, Natalia, and Benjamin N. Roth. "Paying for the Truth: The Efficacy of a Peer Prediction Mechanism in the Field." Working Paper, April 2016.
- August 2020
- Article
A History of Prescription Drug Monitoring Programs in the United States: Political Appeal and Public Health Efficacy
By: A Jay Holmgren, Alyssa Botelho and Allan M Brandt
Prescription drug monitoring programs (PDMPs) have become a widely embraced policy to address the US opioid crisis. Despite mixed scientific evidence on their effectiveness at improving health and reducing overdose deaths, 49 states and Washington, DC have adopted... View Details
Keywords: Health Disorders; Information Technology; Programs; Technology Adoption; History; Government and Politics; Policy; United States
Holmgren, A Jay, Alyssa Botelho, and Allan M Brandt. "A History of Prescription Drug Monitoring Programs in the United States: Political Appeal and Public Health Efficacy." American Journal of Public Health 110, no. 8 (August 2020).
- 31 Oct 2016
- Research & Ideas
Quantitative Easing Didn’t Ease the Housing Crisis for the Neediest
more liquidity would have gone a long way” A new study takes a deep dive into the efficacy of the Fed’s quantitative easing strategy, looking at how the various rounds of QE affected “the real economy”—that is, the part of the economy... View Details
Keywords: by Carmen Nobel
Samuel B. Antill
Samuel Antill is an assistant professor of business administration in the Finance Unit at Harvard Business School. He teaches the Finance II course in the MBA required curriculum.
Professor Antill’s research interests are in corporate... View Details
Professor Antill’s research interests are in corporate... View Details
- 31 Oct 2016
- News
Quantitative Easing Didn’t Ease the Housing Crisis for the Neediest
- January 2021 (Revised March 2021)
- Case
Serum Institute of India (SII): Racing to Save Lives During a Pandemic
By: Rohit Deshpandé, Anjali Raina and Rachna Chawla
The CEO of Serum Institute of India (SII), a $12.8 billion Indian Family business is faced with a risky choice between principles and profit. SII is the largest manufacturer of vaccines in the world and Adar Poonawalla, the CEO and son of the founder has to decide how... View Details
Keywords: Business Ethics; Healthcare; COVID-19; Vaccines; Family Business; Ethics; Health Care and Treatment; Health Pandemics; Leadership; Corporate Accountability; Fairness; Growth and Development Strategy; Health Industry; India; South Asia
Deshpandé, Rohit, Anjali Raina, and Rachna Chawla. "Serum Institute of India (SII): Racing to Save Lives During a Pandemic." Harvard Business School Case 521-028, January 2021. (Revised March 2021.)
- 01 Jun 2012
- News
Leadership Is a Conversation
- December 2020 (Revised April 2021)
- Case
IBM Watson at MD Anderson Cancer Center
By: Shane Greenstein, Mel Martin and Sarkis Agaian
After discovering that their cancer diagnostic tool, designed to leverage the cloud computing power of IBM Watson, needed greater integration into the clinical processes at the MD Anderson Cancer Center, the development team had difficult choices to make. The Oncology... View Details
Keywords: Decision Making; Innovation Strategy; Knowledge Management; Knowledge Use and Leverage; Operations; Failure; Information Technology; Applications and Software; Health Care and Treatment; Product Development; Health Industry; Information Technology Industry; Technology Industry; United States; Houston; Texas
Greenstein, Shane, Mel Martin, and Sarkis Agaian. "IBM Watson at MD Anderson Cancer Center." Harvard Business School Case 621-022, December 2020. (Revised April 2021.)
- 2017
- Article
Affective, Cognitive and Behavioral Trajectories of Change Recipients in Global Organizations
By: B. S. Reiche, T. B. Neeley and N. Overmeyer
Research rarely addresses how change recipients respond to radical change across affective, cognitive, and behavioral dimensions over time. We examined a radical change in a recently acquired subsidiary of a U.S.-based global organization over a two-year period. With... View Details
Keywords: Change; Spoken Communication; Globalized Firms and Management; Behavior; Cross-Cultural and Cross-Border Issues
Reiche, B. S., T. B. Neeley, and N. Overmeyer. "Affective, Cognitive and Behavioral Trajectories of Change Recipients in Global Organizations." Academy of Management Proceedings (2017). (Proceedings of the 77th Annual Meeting (2017), edited by Guclu Atinc. Online ISSN: 2151-6561.)
- 21 Jan 2020
- News
Well-Intentioned Planning for 2020
- Research Summary
Teamwork and Innovative Behavior with Professor Jeff Polzer and Hila Lifshitz
In a field setting, we explore how teamwork could enhance team members' interpersonal relationships and work performance. We collect longitudinal survey data and measure creative performance of a US company's employees before, during, and after they... View Details
- January 2018
- Article
Innovation Incentives and Biomarkers
By: Ariel Dora Stern, Brian M. Alexander and Amitabh Chandra
Previously, we have discussed the importance of economic incentives in shaping markets for precision medicines. Here we consider incentives for biomarker development, including discovery and establishment. Biomarkers can reveal valuable information regarding diagnosis... View Details
Stern, Ariel Dora, Brian M. Alexander, and Amitabh Chandra. "Innovation Incentives and Biomarkers." Clinical Pharmacology & Therapeutics 103, no. 1 (January 2018): 34–36.